Phase 4
N=70
Combined Letrozole and Clomid in Women With Infertility and PCOS
Polycystic Ovary Syndrome · Infertility
Bottom Line
View on ClinicalTrials.gov: NCT02802865 ↗Enrolled (actual)
70
Serious AEs
3.1%
Results posted
Sep 2019
Primary outcome: Primary: Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level — 15; 27 Participants — p=0.007
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Clomiphene (Drug); Letrozole (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Rachel Mejia
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level |
15; 27 | 0.007 sig |
| SECONDARY Number of Developing Follicles |
0; 1 | <0.001 sig |
| SECONDARY Size of Largest Developing Follicle |
10; 16 | 0.004 sig |
| SECONDARY Endometrial Thickness |
6.2; 8.3 | 0.006 sig |
| SECONDARY Conception |
3; 4 | 0.709 |
| SECONDARY Clinical Pregnancy |
1; 3 | 0.356 |
| SECONDARY Multiple Gestation |
0; 0 | — |
| SECONDARY Live Birth |
1; 3 | 0.356 |
| SECONDARY Pregnancy Loss |
2; 1 | 0.486 |
Summary
This study evaluates the addition of clomid to letrozole for the treatment of infertility in women with polycystic ovary syndrome. Half of the participants will receive letrozole and clomid in combination, while the other half will receive letrozole alone.
Eligibility Criteria
Inclusion Criteria
- Willing to comply with all study procedures and be available for the duration of the study
- Diagnosis of infertility: Inability of couple to achieve successful pregnancy after 12 months of regular timed unprotected intercourse in women less than 35 years of age; and after 6 months of regular intercourse without use of contraception in women 35 years and older
- Diagnosis of polycystic ovary syndrome based on Revised Rotterdam criteria
- Ability to have regular intercourse during the ovulation induction phase of the study
- Normal sperm concentration of 15 million/mL and with normal motility of > 40% according to World Health Organization cutoff points, in at least one ejaculate during the previous year
Exclusion Criteria
- Current pregnancy
- Current use of hormonal contraception; use of any type of combined contraceptive or oral progestins within the past month; or use of hormonal implants or depo progestins within the past 3 months
- Other known cause of infertility: endometriosis, tubal factor, uterine abnormalities
- Uncorrected thyroid disease
- Untreated hyperprolactinemia.
- Medical conditions in which avoiding pregnancy is recommended until under improved control: poorly controlled Type 1 or Type 2 diabetes, poorly controlled hypertension
- Contraindications to clomiphene citrate: hypersensitivity to CC or any of its components, history of liver disease or known liver disease, unknown cause of abnormal uterine bleeding, or intracranial lesion
- Contraindications to letrozole: hypersensitivity to letrozole or any of its components.
- Use of medications known to affect reproductive function or metabolism or that are an absolute contraindication during pregnancy within the past month.
- If patients are suspected based on clinical findings for other etiologies that mimic PCOS, work up must be completed to exclude other etiologies prior to enrollment (i.e. Cushing's syndrome, androgen-secreting tumor).
Data sourced from ClinicalTrials.gov (NCT02802865). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.